Issue
Alert me when new journal issues are available via or via
Masthead page iii Full-Text PDF (31 KB)
Editorial board page iv Full-Text PDF (65 KB)
Contents pages vii-viii Full-Text PDF (50 KB)
News and Topics
Making prostate-specific antigen testing more effective William J. Catalona, Stacy Loeb pages 177-179 Full Text | Full-Text PDF (72 KB)
Original Articles
Treatment of stage I seminoma: A 15-year review Ibraheem Alomary, Rajiv Samant, Victor Gallant pages 180-183 Abstract | Full Text | Full-Text PDF (160 KB)
International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels Janet Laura Colli, Albert Colli pages 184-194 Abstract | Full Text | Full-Text PDF (211 KB)
Antiprostasome antibodies: Possible serum markers for prostate cancer metastasizing liability Anders Larsson, Gunnar Ronquist, Christian Wülfing, Elke Eltze, Olaf Bettendorf, Lena Carlsson, B. Ove Nilsson, Axel Semjonow pages 195-200 Abstract | Full Text | Full-Text PDF (144 KB)
Clinical symptoms in localized renal cell carcinoma reflect its invasive potential: Comparative study between incidentally detected and symptomatic diseases Ken-ichi Harada, Iori Sakai, Takeshi Ishimura, Taka-aki Inoue, Isao Hara, Hideaki Miyake pages 201-206 Abstract | Full Text | Full-Text PDF (262 KB)
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer Antonio Rosato, Alessandra Banzato, Gilda De Luca, Davide Renier, Fabio Bettella, Claudio Pagano, Giovanni Esposito, Paola Zanovello, PierFrancesco Bassi pages 207-215 Abstract | Full Text | Full-Text PDF (515 KB)
Prostate adenocarcinoma manifesting as generalized lymphadenopathy Fabiana M. Moura, Luisimara T. Garcia, Lúcia P.F. Castro, Teresa C.A. Ferrari pages 216-219 Abstract | Full Text | Full-Text PDF (194 KB)
Seminar Section Overview
Prostate cancer: Molecular approaches for detection and prognosis, and angiogenic therapeutic targets Hani H. Rashid, Kenneth S. Koeneman pages 220-221 Abstract | Full Text | Full-Text PDF (51 KB)
Seminar Section Introduction I
The application of genomic and proteomic approaches to human prostate cancer in developing diagnostic and prognostic markers James D. Brooks pages 222-223 Full Text | Full-Text PDF (53 KB)
Seminar Articles
Single nucleotide polymorphisms: Early diagnosis and risk assessment in genitourinary malignancy Adam S. Kibel pages 224-230 Abstract | Full Text | Full-Text PDF (160 KB)
Proteomics for the identification of new prostate cancer biomarkers David K. Ornstein, Darren R. Tyson pages 231-236 Abstract | Full Text | Full-Text PDF (436 KB)
Cancer immunomics: Using autoantibody signatures in the early detection of prostate cancer Timothy J. Bradford, Xiaoju Wang, Arul M. Chinnaiyan pages 237-242 Abstract | Full Text | Full-Text PDF (811 KB)
Seminar Section Introduction II
Anti-angiogenic and cytotoxic targeted systemic therapy for high-risk prostate cancer Hani H. Rashid, Joel Nelson, Kenneth S. Koeneman pages 243-245 Abstract | Full Text | Full-Text PDF (62 KB)
The use of thalidomide in androgen-independent prostate cancer Michael C. Cox, William L. Dahut, William D. Figg pages 246-249 Abstract | Full Text | Full-Text PDF (82 KB)
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale Charles J. Ryan, Amy M. Lin, Eric J. Small pages 250-253 Abstract | Full Text | Full-Text PDF (95 KB)
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer Mark Garzotto, Anne Myrthue, Celestia S. Higano, Tomasz M. Beer pages 254-259 Abstract | Full Text | Full-Text PDF (111 KB)
Current status of anti-angiogenesis therapy for prostate cancer Juan Antonio Jiménez, Chinghai Kao, Sudhanshu Raikwar, Thomas A. Gardner pages 260-268 Abstract | Full Text | Full-Text PDF (357 KB)
Survey Section Editorial Board page 269 Full Text | Full-Text PDF (37 KB)
Urologic Oncology Survey
Urothelial neoplasms in patients 20 years or younger: A clinicopathological analysis using the World Health Organization 2004 bladder consensus classification: Fine SW, Humphrey PA, Dehner LP, Amin, MB, Epstein JI, Department of Pathology, Johns Hopkins Hospital, Baltimore, MD H. Barton Grossman page 270 Abstract | Full Text | Full-Text PDF (57 KB)
Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice: Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, Wolff DJ, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC H. Barton Grossman pages 270-271 Abstract | Full Text | Full-Text PDF (63 KB)
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial: Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL, Department of Surgery/Urology, Tor Vergata University, Rome, Italy H. Barton Grossman pages 271-272 Abstract | Full Text | Full-Text PDF (46 KB)
Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder? Manoharan M, Reyes MA, Kava BR, Singal R, Kim SS, Soloway, MS, Department of Urology, University of Miami School of Medicine, Miami, FL H. Barton Grossman page 272 Abstract | Full Text | Full-Text PDF (40 KB)
Gene expression profiling of noninvasive primary urothelial tumours using microarrays: Aaboe M, Marcussen N, Jensen KM-E, Thykjaer T, Dyrskjøt L, Ørntoft TF, Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital Skejby, Aarhus, Denmark H. Barton Grossman page 273 Abstract | Full Text | Full-Text PDF (41 KB)
NAT2 slow acetylation and bladder cancer in workers exposed to benzidine: Carreón T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, Hemstreet GP III, Yin S, LeMasters GK, Division of Surveillance, Hazard Evaluations and Field Studies, National Institute for Occupational Safety and Health, Cincinnati, OH William A. See page 273 Abstract | Full Text | Full-Text PDF (41 KB)
Treatment delay and prognosis in invasive bladder cancer: Liedberg F, Anderson H, Månsson W, Department of Urology, Lund University Hospital, Lund, Sweden William A. See page 274 Abstract | Full Text | Full-Text PDF (41 KB)
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay: Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y, Department of Urology, M.D. Anderson Cancer Center, Houston, TX William A. See pages 274-275 Abstract | Full Text | Full-Text PDF (47 KB)
Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer: Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M, Departments of Urology and Paediatric Urology, Saarland University, Homburg/Saar, Germany William A. See pages 275-276 Abstract | Full Text | Full-Text PDF (47 KB)
Intravesical bacillus Calmette-Guérin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects: Andius P, Fehrling M, Holmäng S, Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden William A. See page 276 Abstract | Full Text | Full-Text PDF (40 KB)
Information for Authors page CO3 Full-Text PDF (35 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
